Every 8-K that FUTURETECH II ACQ CRP UTS (FTIIU) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow FTIIU and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full FTIIU filings page.
FutureTech II Acquisition Corp. obtained stockholder approval to amend its certificate of incorporation and extend the period it has to complete an initial business combination by nine months, moving the deadline from August 18, 2026 to May 18, 2027. This change was effected through a Certificate of Amendment filed with the Delaware Secretary of State.
At the special meeting held on August 13, 2026, stockholders representing 3,904,200 shares of common stock, or 96.1% of the 4,061,674 shares entitled to vote, were present in person or by proxy. The charter amendment proposal received 3,904,200 votes for and no votes against or abstentions, exceeding the required 65% approval threshold.
FutureTech II Acquisition Corp. determined that several prior financial reports contain errors and can no longer be relied upon. The company plans to restate its unaudited results for the three and nine months ended September 30, 2024, the audited year ended December 31, 2024, and the unaudited quarters ended March 31 and June 30, 2025.
Related Forms 10-Q and 10-K that include these financial statements will be amended after the restatements are completed. Management also concluded that disclosure controls and procedures were not effective as of December 31, 2024 and 2025 due to a material weakness in internal control over financial reporting. The company has begun remediation, including engaging a new external advisor and adding controls in its accounting software.
FutureTech II Acquisition Corp. entered into an engagement letter with D. Boral Capital, LLC, appointing D. Boral as sole and exclusive financial advisor for the planned De-SPAC business combination with Longevity Biomedical, Inc. D. Boral receives an irrevocable right of first refusal for 36 months after closing to act as sole investment banker, book-runner, placement agent, or exclusive financial advisor on future equity, debt, and M&A transactions.
The company also corrected a previously disclosed promissory note tied to D. Boral’s deferred underwriting commission of $3,450,000. Instead of full cash at closing, D. Boral agreed to $500,000 in cash, a $1,475,000 promissory note, and 147,500 common shares valued at $10.00 per share. A corrected note clarifies that payment of the $1,475,000 principal is contingent on the closing of the business combination.
FutureTech II Acquisition Corp. has appointed CBIZ CPAs P.C. as its independent registered public accounting firm for the fiscal year ending December 31, 2025. CBIZ will audit the company’s financial statements for 2025 and review its interim financial statements for the three months ended September 30, 2025.
The company states that, during the fiscal years ended December 31, 2025 and 2024 and through February 17, 2026, it did not consult with CBIZ on accounting principles, potential audit opinions, or any matters involving disagreements or reportable events under Regulation S-K.
FutureTech II Acquisition Corp. (FTII) terminated six previously executed Zero Interest Convertible Notes effective November 8, 2025. The notes, issued to individual investors in April 2025, had an aggregate principal of $1,025,000 and were convertible into shares after the closing of the company’s initial business combination.
The notes carried no interest unless the September 30, 2025 maturity date was extended, in which case 5% per annum would apply from the maturity date. No monies were paid to the company by the investors under these notes. With the termination, the notes are of no further force and effect.